MBA MBA - Applied Molecular Chief Officer
| AMTIDelisted Stock | USD 0.33 0.00 0.00% |
Insider
MBA MBA is Chief Officer of Applied Molecular Transport
| Age | 54 |
| Phone | 650 392 0420 |
| Web | https://www.appliedmt.com |
Applied Molecular Management Efficiency
The company has return on total asset (ROA) of (0.5125) % which means that it has lost $0.5125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5805) %, meaning that it created substantial loss on money invested by shareholders. Applied Molecular's management efficiency ratios could be used to measure how well Applied Molecular manages its routine affairs as well as how well it operates its assets and liabilities.Applied Molecular Transport currently holds 36.12 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Applied Molecular has a current ratio of 6.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Applied Molecular's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Thomas Walker | Bio Path Holdings | N/A | |
| Fangyong Du | Adagene | 54 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Jc MD | Adagene | 59 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Qinghai Zhao | Adagene | 63 | |
| Mark Gowland | Fennec Pharmaceuticals | N/A | |
| James Collins | Senti Biosciences | 58 | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Peter MBA | Bio Path Holdings | 75 | |
| Joseph CPA | Inhibikase Therapeutics | 62 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Roger Rush | Inhibikase Therapeutics | N/A | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -1.58 | |||
| Return On Asset | -0.51 |
Applied Molecular Leadership Team
Elected by the shareholders, the Applied Molecular's board of directors comprises two types of representatives: Applied Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Applied. The board's role is to monitor Applied Molecular's management team and ensure that shareholders' interests are well served. Applied Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Applied Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Chang, Head Communications | ||
| Earl Douglas, Exec Counsel | ||
| Bittoo MD, Chief Officer | ||
| Graham Cooper, Ex Chairman | ||
| Shawn Cross, Pres COO | ||
| Tahir Mahmood, CEO CoFounder | ||
| Andy Whitney, VP Science | ||
| MBA MBA, Chief Officer | ||
| Randall Mrsny, CoFounder Director | ||
| Brandon Hants, Chief Officer |
Applied Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Applied Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.58 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (5.88 M) | |||
| Shares Outstanding | 41.85 M | |||
| Shares Owned By Insiders | 21.35 % | |||
| Shares Owned By Institutions | 37.20 % | |||
| Number Of Shares Shorted | 292.87 K | |||
| Price To Book | 0.70 X | |||
| Gross Profit | (42.08 M) | |||
| EBITDA | (127.22 M) |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Applied Stock
If you are still planning to invest in Applied Molecular check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Applied Molecular's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |